These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31155345)

  • 1. Structural Basis for the Inhibition of CRISPR-Cas12a by Anti-CRISPR Proteins.
    Zhang H; Li Z; Daczkowski CM; Gabel C; Mesecar AD; Chang L
    Cell Host Microbe; 2019 Jun; 25(6):815-826.e4. PubMed ID: 31155345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into multistage inhibition of CRISPR-Cas12a by AcrVA4.
    Peng R; Li Z; Xu Y; He S; Peng Q; Wu LA; Wu Y; Qi J; Wang P; Shi Y; Gao GF
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):18928-18936. PubMed ID: 31467167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1.
    Yamano T; Zetsche B; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Aug; 67(4):633-645.e3. PubMed ID: 28781234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a.
    Knott GJ; Cress BF; Liu JJ; Thornton BW; Lew RJ; Al-Shayeb B; Rosenberg DJ; Hammel M; Adler BA; Lobba MJ; Xu M; Arkin AP; Fellmann C; Doudna JA
    Elife; 2019 Aug; 8():. PubMed ID: 31397669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Insights into the cis- and trans-Acting DNase Activities of Cas12a.
    Swarts DC; Jinek M
    Mol Cell; 2019 Feb; 73(3):589-600.e4. PubMed ID: 30639240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized protocols for the characterization of Cas12a activities.
    Martin L; Rostami S; Rajan R
    Methods Enzymol; 2023; 679():97-129. PubMed ID: 36682874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad-spectrum enzymatic inhibition of CRISPR-Cas12a.
    Knott GJ; Thornton BW; Lobba MJ; Liu JJ; Al-Shayeb B; Watters KE; Doudna JA
    Nat Struct Mol Biol; 2019 Apr; 26(4):315-321. PubMed ID: 30936531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryo-EM structure of the RNA-guided ribonuclease Cas12g.
    Li Z; Zhang H; Xiao R; Han R; Chang L
    Nat Chem Biol; 2021 Apr; 17(4):387-393. PubMed ID: 33495647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making the cut(s): how Cas12a cleaves target and non-target DNA.
    Swarts DC
    Biochem Soc Trans; 2019 Oct; 47(5):1499-1510. PubMed ID: 31671185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A scoutRNA Is Required for Some Type V CRISPR-Cas Systems.
    Harrington LB; Ma E; Chen JS; Witte IP; Gertz D; Paez-Espino D; Al-Shayeb B; Kyrpides NC; Burstein D; Banfield JF; Doudna JA
    Mol Cell; 2020 Aug; 79(3):416-424.e5. PubMed ID: 32645367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of target specificity of CRISPR-Cas12a by using a chimeric DNA-RNA guide.
    Kim H; Lee WJ; Oh Y; Kang SH; Hur JK; Lee H; Song W; Lim KS; Park YH; Song BS; Jin YB; Jun BH; Jung C; Lee DS; Kim SU; Lee SH
    Nucleic Acids Res; 2020 Sep; 48(15):8601-8616. PubMed ID: 32687187
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Yu L; Marchisio MA
    ACS Synth Biol; 2021 Apr; 10(4):870-883. PubMed ID: 33819020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for self-cleavage prevention by tag:anti-tag pairing complementarity in type VI Cas13 CRISPR systems.
    Wang B; Zhang T; Yin J; Yu Y; Xu W; Ding J; Patel DJ; Yang H
    Mol Cell; 2021 Mar; 81(5):1100-1115.e5. PubMed ID: 33472057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mg
    Son H; Park J; Hwang I; Jung Y; Bae S; Lee S
    Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34853172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing noncanonical crRNA for highly efficient genome editing.
    Xun G; Zhu Z; Singh N; Lu J; Jain PK; Zhao H
    Nat Commun; 2024 May; 15(1):3823. PubMed ID: 38714643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Basis for the Altered PAM Recognition by Engineered CRISPR-Cpf1.
    Nishimasu H; Yamano T; Gao L; Zhang F; Ishitani R; Nureki O
    Mol Cell; 2017 Jul; 67(1):139-147.e2. PubMed ID: 28595896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2'-O-methylated uridinylate-rich 3'-overhang in mouse zygotes.
    Ha DI; Lee JM; Lee NE; Kim D; Ko JH; Kim YS
    Exp Mol Med; 2020 Nov; 52(11):1823-1830. PubMed ID: 33162553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryo-EM structure of the transposon-associated TnpB enzyme.
    Nakagawa R; Hirano H; Omura SN; Nety S; Kannan S; Altae-Tran H; Yao X; Sakaguchi Y; Ohira T; Wu WY; Nakayama H; Shuto Y; Tanaka T; Sano FK; Kusakizako T; Kise Y; Itoh Y; Dohmae N; van der Oost J; Suzuki T; Zhang F; Nureki O
    Nature; 2023 Apr; 616(7956):390-397. PubMed ID: 37020030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.